Novartis’s 177Lu-PSMA-617 reduces prostate cancer death risk by 38%
pharmafile | June 4, 2021 | News story | Medical Communications |
Novartis’s 177Lu-PSMA-617 has shown to significantly improve overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in a Phase III trial.
Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death and a 60% reduction in the risk of radiographic disease progression or death compared to best standard of care alone.
Patients receiving 177Lu-PSMA-617 also demonstrated a statistically significant 60% risk reduction for radiographic progression-free survival or death compared to best standard of care only.
Michael J Morris, MD, who chaired the study’s Scientific Committee, said: “Patients suffering from metastatic CRPC who have progressed through contemporary hormonal treatments and chemotherapy have few meaningful therapeutic options.
“The study demonstrated that 177Lu-PSMA-617 improves disease progression and prolongs survival, which are key measures of clinical benefit in the mCRPC population. I am grateful to be a part of this study that may lead to additional therapeutic options for these patients.”
John Tsai, Head of Global Drug Development and Chief Medical Officer for Novartis, said: “Men with metastatic prostate cancer have an approximately 3 in 10 chance of surviving 5 years.
“These data from the first Phase III study of a radioligand therapy in this advanced prostate cancer setting confirm the potential of 177Lu-PSMA-617 targeted therapy to improve clinical outcomes.
“Our comprehensive development program for this targeted therapy seeks to reach eligible patients with advanced prostate cancer, who express the PSMA biomarker. And, we won’t stop with prostate cancer, our team is exploring next generation RLT across a number of tumour types.”
Prostate cancer is a form of cancer that develops in the prostate gland, a small walnut shaped gland in the pelvis of men. The five-year survival rate for patients with metastatic prostate cancer is approximately 30%.
Lilly Subbotin
